Skip to content

College Station, Texas 77807

FLOVID-20

TARGETED T-CELL IMMUNOTHERAPY

A treatment for new COVID-19 patients. Administered by inhaler.

Designed to prevent severe COVID-19 disease and cure COVID ‘long-haulers’.

Under Development. FDA Approval Required.

FLOVID-20

Targeted T-Cell Immunotherapy

Predicted to work against all variants
of COVID-19 Virus

FLOVID-20

Targeted T-Cell Immunotherapy

Predicted to work against all variants
of COVID-19 Virus

About Strategic Vaccines A public private partnership created
to commercialize targeted T-Cell Immunotherapy
for treatment and prevention of viral diseases

COVID-19 patients
expect effective treatment.
FLOVID-20 will provide the Efficacy, Safety, and Convenience patients seek.

benefit-cross

Efficacy Designed to eliminate severe disease, hospitalization, death,
and 'long-hauler syndrome'

benefit-scope

Safety Assembled from FDA approved components
Pre-clinical studies show no adverse events

benefit-steth

Convenience inhaled, single dose, patient-friendly, simple

Founding companies

Home

Partner companies

Founding companies

Home

Partner companies

Contact us for more information

Contact Information

College Station, Texas 77807
1-925-933-4414